In this issue:
IMmotion010 finds no benefit to adjuvant atezolizumab in RCC
KEYNOTE-564: adjuvant pembrolizumab prolong DFS in clear cell RCC
Long-term outcomes of SABR for RCC
Axitinib/pembrolizumab vs ipilimumab/nivolumab for metastatic RCC
QoL for second-line lenvatinib 14 or 18 mg/day for kidney cancer
Olaparib plus cediranib combo prolongs PFS in metastatic CRPC
FORT-1: rogaratinib for FGFR1/3 mRNA-expressing bladder tumours
Body composition linked to risk of death in prostate cancer patients
Worse outcomes with ICI-based combos in RCC patients with poor PS
FDG-PET optimises watch and wait in good/intermediate prognosis RCC
Metformin does not protect against metabolic complications of ADT
Please login below to download this issue (PDF)